Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

2013 trends

Biotech Innovation in the Time of COVID-19

Chris Garabedian, CEO of Xontogeny, dives into biotech and digital health innovation, current industry gaps and obstacles, how to encourage biotech entrepreneurs, AI & machine learning, and much more!

Impetus Digital

- PMLiVE

Breaking Internal Silos to Ensure Patient Centricity is a Key Focus Company-Wide

Mark and Urs will be discussing the pros and cons of an enterprise-wide approach to patient centricity, and explore the measurable benefits it could deliver. • Who should be involved...

- PMLiVE

Geoff Thorne joins FH as Chief Technology Officer to drive innovation for clients

The experienced executive will expand our cross-functional omnichannel, data and analytics, and technology offerings, developing effective solutions to meet our clients’ evolving needs.

Avalere Health

- PMLiVE

NICE rejects AstraZeneca and MSD’s Lynparza as NHS prostate cancer treatment

The drug will not be available as a treatment option for men with prostate cancer in England and Wales

- PMLiVE

NHS to move ahead with Pfizer/BioNTech bivalent COVID-19 vaccine roll-out

The autumn booster programme launches today

New syndicated patient reports –

Living with Uterine Fibroids and Endometriosis US 2022

Inizio

Steve Chick OPEN Health

Steve Chick joins OPEN Health as Chief Growth Officer for Evidence & Access

OPEN Health is pleased to announce the appointment of Stephen J. Chick as Chief Growth Officer for OPEN Health Evidence & Access.

OPEN Health

- PMLiVE

Medscape: Education that delivers skin in the game #EADVCongress

Medscape Education Global to Present Symposia and Posters at the European Academy of Dermatology and Venereology 2022 (EADV)

Medscape Education

- PMLiVE

Bristol Myers Squibb’s acute myeloid leukaemia oral maintenance therapy recommended by NICE

Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival

- PMLiVE

Sanofi and Regeneron share positive data for asthma drug

The trial evaluated the drug for children aged six to 11 years with moderate-to-severe asthma

The Sofa Sessions – Fourth Page

Page & Page Health

- PMLiVE

Qureight announces world’s first digital biomarker for lung fibrosis will ‘transform’ clinical trials

The AI-based Lung8 imaging software picked up differences in response between patients who had an experimental drug compared with those who took a placebo

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links